Home › Compound Library
84 Research Compounds

Compound Library

Evidence-based research summaries for 84 peptides across 9 categories. Mechanisms, pharmacokinetics, trial data, and citations.

Research-Only Citation-Backed Evidence-Graded
10 compounds in GLP-1 & Metabolic Research
Tirzepatide
SKUs: TR5, TR10, TR15, TR20 +4 more
High Evidence
GLP-1 & Metabolic

Dual GIP/GLP-1 receptor agonist extensively studied in SURMOUNT and SURPASS trials for metabolic health and weight management research.

Half-life: ~5 days
Retatrutide
SKUs: RT5, RT10, RT15, RT20 +4 more
High Evidence
GLP-1 & Metabolic

Triple agonist (GIP/GLP-1/Glucagon) under phase 2/3 investigation. Early trials show remarkable metabolic and weight-reduction signals.

Half-life: ~6 days
Semaglutide
SKUs: SM5, SM10, SM15, SM20 +1 more
High Evidence
GLP-1 & Metabolic

Highly studied GLP-1 receptor agonist. STEP and SUSTAIN trial programs constitute some of the largest peptide clinical trial bodies in history.

Half-life: ~7 days
Survodutide
SKUs: SUR10
Moderate Evidence
GLP-1 & Metabolic

GLP-1/Glucagon dual agonist under active phase 2/3 investigation for metabolic and NASH research.

Half-life: ~5–6 days
AOD9604
SKUs: 5AD
Preliminary
GLP-1 & Metabolic

Fragment of HGH (amino acids 176-191) studied specifically for lipolytic activity without the growth-promoting effects of full HGH.

Half-life: ~2–3 hours
5-Amino-1MQ
SKUs: 5AM, 50AM
Emerging
GLP-1 & Metabolic

Small molecule NNMT inhibitor studied for its potential in obesity and metabolic disease research contexts.

Half-life: Estimated 2–4 hours based on preclinical data
Liraglutide
SKUs: LIR6, LIR18
High Evidence
GLP-1 & Metabolic

First-generation GLP-1 receptor agonist (Victoza/Saxenda). Once-daily injectable studied extensively for T2D glycemic control and obesity. Foundational molecule in the GLP-1 research class.

Half-life: ~13 hours; allows once-daily dosing
Orforglipron
SKUs: ORF4, ORF8
Preliminary
GLP-1 & Metabolic

Oral non-peptide small molecule GLP-1 receptor agonist. First-in-class daily pill format studied as an alternative to injectable GLP-1 therapies. Phase 3 trials underway (Eli Lilly).

Half-life: ~12–18 hours supporting once-daily oral dosing
Danuglipron
SKUs: DAN4, DAN12
Preliminary
GLP-1 & Metabolic

Twice-daily oral small molecule GLP-1 receptor agonist (Pfizer). Studied as pill-format GLP-1 alternative. Phase 3 program paused 2024 due to GI tolerability; research continues on modified release formulations.

Half-life: ~4–6 hours; requires twice-daily dosing
GLP-1/GIP/Glucagon Triple Agonist
SKUs: TRI5
Emerging
GLP-1 & Metabolic

Next-generation triple receptor agonist research class (GLP-1 + GIP + glucagon). Represents the frontier beyond tirzepatide dual agonism. Several candidates in research including LY3305677 and CT-996.

Half-life: Candidate-dependent; weekly dosing targeted for clinical candidates
Research Reference Only: All compound information on this page is sourced from published scientific literature for educational purposes only. This is not medical advice. These compounds are not approved for human consumption. Regulatory status varies by jurisdiction. Consult qualified medical professionals before making any health decisions.